（编辑 王雪儿） 证券日报网讯 TCL科技10月24日在互动平台回答投资者提问时表示，公司高度重视与广大投资者的沟 通，在遵守信息披露规则的前提下，真诚、有效地回应投资者关切，并将持续优化沟通方式，提升投资 者体验。 ...

（编辑 王雪儿） 证券日报网讯 多瑞医药10月24日在互动平台回答投资者提问时表示，公司将继续严格按照《公司法》 《上市公司治理准则》《上市公司章程指引》及其他相关法律法规的要求，确立由股东会、董事会和管 理层组成的公司治理结构，并进一步建立健全相关制度。同时，公司将进一步加强与投资者的沟通，通 过多种渠道主动与股东特别是中小股东进行沟通和交流，充分听取中小股东的意见和诉求，并及时答复 中小股东关心的问题。公司将持续提升信息披露质量，确保信息披露的真实、准确、完整、及时、公 平。 ...

Group 1 - The company, Lijun Group, is committed to holding regular performance briefings to communicate its operational status to investors [1] - The communication channels between the company and investors are diverse and effective, ensuring ongoing dialogue [1] - The company plans to enhance its communication with investors through various means and will continue to prioritize information disclosure to convey its value to the market [1]

Core Insights - The company's recent results were below expectations, leading to initial pressure on the stock price, which has since recovered to pre-release levels [1] - Investor communication has focused on initiatives to accelerate earnings and general expectations beyond 2025 [2] Financial Performance - The company experienced a temporary decline in stock price following the release of results, but it has rebounded to previous levels, indicating investor confidence [1] - Ongoing discussions with investors have aimed to clarify the company's strategies for future earnings growth [2]

Group 1 - Company will participate in the 2025 semi-annual performance briefing for the innovative drug industry on September 16, 2025, from 15:00 to 17:00 [2][3][4] - Investors can submit questions for the briefing from September 9 to September 15, 2025, through the Shanghai Stock Exchange Roadshow Center website or via the company's email [2][4] - The briefing will be conducted in an online text interaction format, allowing investors to engage with the company [2][3] Group 2 - The company will hold its first extraordinary general meeting of 2025 on September 15, 2025, at 10:00 AM, with both on-site and online voting options available [8][9] - The meeting will discuss various resolutions, including the approval of the 2025 semi-annual report and the special resolution regarding the cancellation of the supervisory board [11][12][33] - The company emphasizes the importance of shareholder participation and has set up a reminder service to ensure small and medium investors are informed about the meeting [20] Group 3 - The company reported significant progress in its drug development pipeline, focusing on innovative small molecule anti-cancer drugs [37][38] - Key candidates such as SY-707 and SY-5007 have reached important milestones, with SY-5007 preparing for a new drug application submission [39][40] - The company is also expanding its research and development capabilities by establishing a new drug research and industrialization base with an investment of up to 787 million yuan [44][45] Group 4 - The company has maintained a strong financial position, with total assets of 819.45 million yuan and no interest-bearing liabilities as of mid-2025 [46] - Cash management strategies have yielded a return of 9.44 million yuan during the reporting period, ensuring liquidity and safety of funds [46] - The company has actively engaged in investor communication, hosting multiple events to enhance transparency and information dissemination [49][50]